PMID- 34745885
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211110
IS  - 2214-2509 (Print)
IS  - 2214-2509 (Electronic)
IS  - 2214-2509 (Linking)
VI  - 26
DP  - 2021
TI  - Utilization of whole genome sequencing for resolution of discrepant Mycobacterium 
      tuberculosis drug susceptibility results: A case report.
PG  - e01308
LID - 10.1016/j.idcr.2021.e01308 [doi]
LID - e01308
AB  - A 44-year-old woman undergoing therapy for acute promyelocytic leukemia (APL) 
      developed disseminated tuberculosis. Mycobacterium tuberculosis (TB) was isolated 
      from the blood and sputum. Initial drug susceptibility testing (DST) of the blood 
      isolate revealed resistance to isoniazid and ethambutol but the sputum isolate 
      showed no resistance. Due to drug resistance concerns, the patient was treated 
      with multiple second and third-line drugs, and suffered from drug side effects. 
      To further investigate the DST discrepancies, whole genome sequencing (WGS) was 
      performed on both isolates. No known resistance mutations to first line or second 
      line drugs were identified in either isolate, which was confirmed by additional 
      susceptibility testing performed by a different reference laboratory and the 
      California Department of Public Health (CDPH) laboratory. Treatment was reduced 
      to a simpler and less toxic regimen due to these investigations. WGS is shown to 
      be a valuable tool for resolving discordant phenotypic DST results of TB isolates 
      and has the potential to provide accurate and timely results guiding appropriate 
      therapy in the clinical setting.
CI  - (c) 2021 The Authors.
FAU - Realegeno, Susan
AU  - Realegeno S
AD  - UCLA Clinical Microbiology Laboratory, Department of Pathology & Laboratory 
      Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
FAU - Adeyiga, Oladunni
AU  - Adeyiga O
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, USA.
FAU - Winston, Drew J
AU  - Winston DJ
AD  - Division of Hematology and Oncology, Department of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, USA.
FAU - Beaird, Omer E
AU  - Beaird OE
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      California, Los Angeles, Los Angeles, CA, USA.
FAU - Garner, Omai B
AU  - Garner OB
AD  - UCLA Clinical Microbiology Laboratory, Department of Pathology & Laboratory 
      Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
FAU - Yang, Shangxin
AU  - Yang S
AD  - UCLA Clinical Microbiology Laboratory, Department of Pathology & Laboratory 
      Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
LA  - eng
PT  - Case Reports
DEP - 20211008
PL  - Netherlands
TA  - IDCases
JT  - IDCases
JID - 101634540
PMC - PMC8551521
OTO - NOTNLM
OT  - DST
OT  - Drug resistance prediction
OT  - Mycobacterium tuberculosis
OT  - Whole genome sequencing
COIS- All authors declared no conflict of interest.
EDAT- 2021/11/09 06:00
MHDA- 2021/11/09 06:01
PMCR- 2021/10/08
CRDT- 2021/11/08 06:46
PHST- 2021/08/20 00:00 [received]
PHST- 2021/10/05 00:00 [revised]
PHST- 2021/10/07 00:00 [accepted]
PHST- 2021/11/08 06:46 [entrez]
PHST- 2021/11/09 06:00 [pubmed]
PHST- 2021/11/09 06:01 [medline]
PHST- 2021/10/08 00:00 [pmc-release]
AID - S2214-2509(21)00264-X [pii]
AID - e01308 [pii]
AID - 10.1016/j.idcr.2021.e01308 [doi]
PST - epublish
SO  - IDCases. 2021 Oct 8;26:e01308. doi: 10.1016/j.idcr.2021.e01308. eCollection 2021.